Acta Scientific Medical Sciences (ASMS)(ISSN: 2582-0931)

Case Report Volume 5 Issue 12

Severe Thrombocytopenia Cured After Ovarian Tumours Surgical Removal

Cosmina Andreea Catoiu1, Ioan Corneliu Tanase1,2*, Bogdan Gabriel Stoica1,2 and Sorin Constantin Paun1,2

1Department of Surgery, Emergency Hospital - Bucharest, Romania
2University of Medicine and Pharmacy Carol Davila Bucharest, Romania

*Corresponding Author: Ioan Corneliu Tanase, Assistant Professor, University of Medicine and Pharmacy Carol Davila Bucharest, Department of Surgery, Emergency Hospital - Bucharest, Romania.

Received: October 27, 2021; Published: November 10, 2021


Autoimmune thrombocytopenia (ITP) is an acquired immune-mediated disorder characterized by early platelet destruction due to antiplatelet autoantibodies. Although progress in the immunopathology of ITP has been done, pathogenesis of ITP remains yet to be determined, and currently there are no specific tests that can diagnose this disease, often being a diagnosis of exclusion. We describe the case of a 65-year-old woman admitted in the surgical department with progressively worsening abdominal distension for the past 12 months. Imagistic investigations showed a giant cystic tumour with a distinct septum and inhomogeneous internal content, which extended from the pelvis all the way through the upper abdomen, suggesting a complex left ovarian cyst with no lymph nodes or other intraabdominal tumoural masses. Blood tests showed mild anaemia, and severe thrombocytopenia with a platelet count of 21.000/μL refractory to treatment, anisocytosis with micro- and macro-thrombocytes. Coagulation profile was normal. The patient underwent, total hysterectomy with bilateral adnexectomy pelvic and inter-aortic-caval lymphadenectomy, with the excision of the multiloculated ovarian mass with haemorrhagic fluid and solid components. The histopathological exam showed an ovarian mucinous borderline tumour without stromal or regional lymph node invasion staged T1aN0M0. In the postoperative period we observed the resolution of the thrombocytopaenia, the patient’s platelet count remaining stable around 120000/µL.

This report highlights the causality between the complete ITP remissions after tumour excision suggesting that a possible paraneoplastic implication should always be investigated in such cases. The ovarian tumour presence may be frequently omitted and refractory thrombocytopenia attributed to other causes or classified as idiopathic

Keywords: Thrombocytopenia; Ovarian Tumour; Surgery


  1. Kistanguri G., et al. “Immune Thrombocytopenia”. Hematology/Oncology Clinics of North America 3 (2013): 495‐520.
  2. Stasi R., et al. “Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia”. PLOS Medicine 3 (2006): e24.
  3. Krauth MT., et al. “Paraneoplastic autoimmune thrombocytopenia in solid tumours”. Clinical Reviews in Oncology/Hematology 81 (2012): 75-81.
  4. Rodeghiero F., et al. “Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group”. Blood 113 (2009): 2386-2393.
  5. Abrahamson PE., et al. “The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review”. European Journal of Haematology 2 (2009): 83-89.
  6. Chehal A., et al. “Idiopathic thrombocytopenic purpura and ovarian cancer”. European Journal of Gynaecological Oncology 24 (2003): 539-540.
  7. Lambert MP., et al. “Clinical updates in adult immune thrombocytopenia”. Blood21 (2017): 2829.
  8. Bellucci S., et al. “Association of autoimmune thrombocytopenic purpura (AITP), Graves’ disease and ovarian carcinoma”. NouvelleRevue Francaise d'Hematologie 33 (1991): 307-309.
  9. Shimada T., et al. “Immune thrombocytopenia associated with solid cancer”. Journal of Obstetrics and Gynaecology Research9 (2015): 1495-1498.
  10. Hudson CN., et al. “Paraneoplastic syndromes in patients with ovarian neoplasia”. Journal of the Royal Society of Medicine 86 (1993): 202-204.
  11. Schwartz KA., et al. “Immune-mediated platelet destruction and thrombocytopenia in patients with solid tumours”. The British Journal of Haematology 51 (1982): 17-24.
  12. Kim HD., et al. “A syndrome resembling idiopathic thrombocytopenic purpura in 10 patients with diverse forms of cancer”. The American Journal of Medicine 67 (1979): 371-377.
  13. Soma-Pillay P., et al. “A rare case of idiopathic thrombocytopenia in association with an ovarian teratoma in pregnancy”. Obstetric Medicine3 (2009): 126-127.
  14. Khalife D., et al. “Ovarian teratoma: yet another cause of immune thrombocytopenia”. The International Journal of Women's Health 10 (2018): 567-570.
  15. Ai S S Y., et al. “Immune thrombocytopenia in the setting of ovarian dermoid cysts: implications for diagnosis and management” The Internal Medicine Journal10 (2018): 1275-1276.
  16. Garnick MB., et al. “Idiopathic thrombocytopenia in association with extragonadal germ cell cancer”. Annals of Internal Medicine6 (1983): 926-927.
  17. Tang P., et al. “Mature cystic teratoma of the ovary associated with complete colonic wall and mucinous cystadenoma”. Annals of Clinical and Laboratory Science4 (2003): 465-470.
  18. Shen Q., et al. “Co-existing mature cystic teratoma and borderline ovarian mucinous cystadenoma: a report of three cases”. International Journal of Clinical and Experimental Medicine5 (2018): 5227-5231.
  19. Roy S., et al. “Mature Cystic Teratoma with Co-existent Mucinous Cystadenocarcinoma in the same Ovary-A Diagnostic Dilemma”. Journal of Clinical and Diagnostic Research12 (2016): ED11-ED13.
  20. Ueda G., et al. “Adenocarcinoma in a benign cystic teratoma of the ovary: Report of a case with a long survival period”. Gynecologic Oncology (1993): 259-263.


Citation: Sorin Constantin Paun., et al. “Severe Thrombocytopenia Cured After Ovarian Tumours Surgical Removal”.Acta Scientific Medical Sciences 5.12 (2021): 21-25.


Copyright: © 2021 Ioan Corneliu Tanase., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is July 10, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US